Supplemental Figure 2

By B. Mimee, Marc‐Olivier Duceppe, Pierre-Yves Véronneau, Joël Lafond-Lapalme, M. Jean, François Belzile, G. Bélair. 2014

738 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer (2015, background): “In addition to interaction with cell surface receptors that initiate signaling pathways that impair vascular function (138), HA can increase interstitial fluid pressure and form a physical barrier against movement of small molecule”
An Introduction to Proteoglycans and Their Localization (2012, background): “2012), and in some cases, hyaluronan-rich matrices may impede drug delivery or access to cell surface receptors, for example, ErbB2 (Jacobetz et al. 2012; Váradi et al. 2012).”
Organoid profiling identifies common responders to chemotherapy in pancreatic cancer (2018, background): “430 The poor response of PDAC patients to therapies has been attributed to neoplastic cell characteristics such 431 as cancer stem cells (17), redox metabolism (27) and intermediary metabolism (28, 29); and to non-cell 432 autonomous properties such as limited drug delivery (30-32), impaired intra-t”
Organoid Models of Human and Mouse Ductal Pancreatic Cancer (2014, methodology): “…intraepithelial neoplasms (PanINs) (Hingorani et al., 2003; Pérez-Mancera et al., 2012) and were used to discover that PDA possesses a deficient vasculature that impairs drug delivery (Erkan et al., 2009; Jacobetz et al., 2013; Koong et al., 2000; Olive et al., 2009; Provenzano et al., 2012).”